SEC Form 4 · accession 0001209191-17-029272
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Apr 28, 2017
Accepted (ET)
May 2, 2017 · 5:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 28, 2017 | M | 28,320 | $45.11 | A | 159,567 | D | |
| Common Stock | Apr 28, 2017 | S | 28,320 | $119.50 | D | 131,247 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401k |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $45.11 | Apr 28, 2017 | M | 28,320 | D | — | Feb 4, 2023 | Common Stock | 28,320 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- F2Fully vested.